Fund+ in the news.

source date title
Press release 3 Juni 2019

eTheRNA announces Safety and immune stimulation data from an intranodal delivery of TriMix mRNA, in the adjuvant melanoma study E011-MEL

Press release 3 Juni 2019

eTheRNA immunotherapies appoints Chief Financial Officer

Press release 3 Juni 2019

Minoryx Therapeutics announces first patient dosed in the FRAMES phase 2 trial in Friedreich’s Ataxia

Press release 23 Mei 2019

Novadip Biosciences presents data at 30th annual EURAPS Research Council Meeting

Press release 20 Mei 2019

EyeD Pharma successfully raises €28 million

Press release 7 Mei 2019

Confo Therapeutics raises €30 million in Series A financing

Press release 7 Mei 2019

Promethera Biosciences completes €39,7 million ($44,4 million) Series D financing

Press release 12 April 2019

Immunic Therapeutics and Vital Therapies complete transaction creating Nasdaq-listed company targeting chronic inflammatory and autoimmune diseases

Press release 12 Maart 2019

Minoryx Therapeutics appoints Didier Le Normand as Group Chief Financial Officer (CFO) and General Manager of its Belgian subsidiary

Press release 27 Februari 2019

Minoryx Therapeutics receives approval from Spanish Regulatory Agency to initiate phase 2 study in Friedreich’s Ataxia

Press release 26 Februari 2019

Immunic Therapeutics announces First Patient enrolled in Phase 2 Clinical Trial of IMU-838, an Oral Therapy for Patients with Relapsing-Remitting Multiple Sclerosis

l’Echo 16 Januari 2019

La biotech espagnole Minoryx installe une filiale dans le Biopark de Gosselies

Press release 07 Januari 2019

Vital Therapies and Immunic Therapeutics Announce Transaction to Create Leading Inflammatory and Autoimmune Disease Company

Press release 02 Januari 2019

Promethera – Japanners pompen 10 miljoen in Waalse levertherapie

Press release 21 December 2018

EPICS Therapeutics to Acquire Ogeda former assets, Adding Drug Discovery & Development Capabilities

Press release 12 December 2018

Novadip Biosciences appoints Jeff Abbey as CEO

Press release 18 September 2018

Minoryx Therapeutics raises € 21.3M in series B funding round

Press release 18 September 2018

Horama completes its 22,5 million “series B” financing round

Press release 15 May 2018

Horama appoints Dr Russell Greig as new chairman of the board

Press release 11 December 2017

New VIB start-up Aelin Therapeutics secures 27 M€ to exploit its proprietary Petp-in protein knockdown platform

Press release 8 November 2017

Horama raises € 19 million in Series B financing round

De Tijd 14 October 2017

BioTech, de geldmachine van Désiré Colen

De Tijd 14 October 2017

Kassa rinkelt voor investeerders bio-tech

L’Echo 14 October 2017

Fund+ monte à 200millions gràce à la plus-value d’Ogeda

Press release 5 September 2017

Immunic Therapeutics adds new investors and completes series A financing round of total EUR 31,7 Million

Press release 29 Augustus 2017

Dosing of First Patient with investigational agent OMO-1

Press release 28 July 2017

iTeos Therapeutics granted EUR 7.5 Million Non-Dilutive Funding by the Walloon Region

Press release 3 April 2017 Astellas to Acquire Ogeda SA – Acquisition Expands Astellas’ Late Stage Clinical Pipeline with Fezolinetant
Press release 19 January 2017 Octimet Oncology NV secures over EUR 11 million to develop it highly selective MET kinase inhibitors
Biotech Finances 31 October 2016 Le francophile de la semaine: Chris Buyse
European Biotechnology 28 October 2016 Belgian Fund+ raises €125  for biotech
Press release 28 October 2016 Promethera Biosciences raises eur 10 million in a series c-extension financing to advance its broad product pipeline in liver diseases
L’Echo 27 October 2016 Désiré Collen. Le scientifique qui fait fructifier les pépites.
Press release 26 October 2016 Fund+ announces eur 125 million closing of Life Sciences Impact Fund. Dr Debasish Roychowdhury appointed independent board member and Chairman of the Scientific Guidance Committee
L’Echo 19 October 2016 Fund+ prêt à investir 125 milions dans les biotechs belges.
L’Echo 19 October 2016 Après 18 mois d’activité, Fund+ est déjà le plus gros fonds biotech belge
eTheRNA 14 March 2016 eTheRNA secures EUR 24 million to develop its – TriMix mRNA-based immunotherapy
Press release 10 February 2016 Euroscreen SA appoints Dr. Philippe Monteyne and Dr. Jean-Paul Prieels to its Board of Directors
Press release 25 January 2016 Amatsigroup acquires Q-Biologicals and strenghens its offering for international pharmaceutical groups.
puurADMB December 2015 Lichtpunten in de wetenschap, Professor Désiré Collen, arts, chemicus en oprichter van ThromboGenics
De Tijd 19 December 2015 De Scheidingsmuur tussen profit en non-profit begint te barsten.
Knack 17 June 2015 Biotechnologie: de belangrijkste spelers en investeerders in Vlaanderen. Op zoek naar het supermedicijn.
L’Echo 5 June 2015 Le nouveau project du fondateur de ThromboGenics.
Trends 11 December 2014 Désiré Collen richt investeringsfonds van 100 miljoen eur op – Investeringen tegen struikroverij.





























ENG_PRESS RELEASE Aelin_11122017

ENG_PRESS RELEASE Aelin_11122017

ENG_PRESS RELEASE Aelin_11122017





press release 3 April 2017

ETheRNA press release 14 March 2016

ETheRNA press release 14 March 2016

ETheRNA press release 14 March 2016

ETheRNA press release 14 March 2016

ETheRNA press release 14 March 2016